JBJeroen de Bresser

Jeroen de Bresser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeroen de Bresser has a total of 555 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Air pollution, neighbourhood walkability and cerebrovascular small vessel disease in patients with cardiovascular disorders along the heart-brain axis

    by Ina Rissanen, Erik J. Timmermans, Jeroen de Bresser, Esther E. Bron, Anna E. Leeuwis, Majon Muller, Matthias J.P. van Osch, Betty M. Tijms, Geert Jan Biessels, Ilonca Vaartjes

  • Open Access

    Bayesian networks to estimate prognosis in vascular cognitive impairment and small vessel disease: Integrated analyses of interdependent contributors to multiple outcomes

    by Malin Overmars, Cor Allaart, Esther E Bron, Hans-Peter Brunner La Rocca, Jeroen de Bresser, Majon Muller, Matthias Jp van Osch, Charlotte Teunissen, Betty M Tijms, Frank J Wolters, et al.

    Background: Vascular cognitive impairment (VCI) and small vessel disease (SVD) involve interconnected factors influencing multiple outcomes, also beyond cognitive decline. Bayesian networks (BNs) can help unravel these complex interrelations, which we demonstrate in this proof-of-concept study in the Heart-Brain Connection cohort, including memory-clinic patients with SVD, patients with heart failure, carotid occlusive disease, and reference participants. Methods: We trained BNs and jointly modelled cognitive decline (Clinical Dementia Rating (CDR) increase) and major adverse cardiovascular events (MACE) over 5 years as outcomes in relation to multiple demographic and disease factors and emerging imaging and plasma biomarkers, also considering non-random study discontinuation. Results: Of 566 individuals (median age 68, 64% men), 80 had MACE and 112 experienced CDR increase. Diagnostic group and baseline cognition were key determinants of both outcomes. The BN identified baseline clinical severity as a non-random study discontinuation source. Plasma biomarkers formed an interconnected subnetwork, linked to demographic and vascular factors, but without direct dependencies with outcomes. The trained BN provides individualized inference under partial evidence, informing on outcome probabilities. Conclusion: This proof-of-concept study demonstrates how BNs quantify and visualize the dependency structure underlying prognostic heterogeneity in VCI and SVD, including non-random study discontinuation and positioning of emerging biomarkers.

  • Open Access

    Non-invasive characterization of perivascular subarachnoid spaces

    by Nina E. Fultz, Geir Ringstad, Madda Debiasi, Emiel C. A. Roefs, Siri Fløgstad Svensson, Per Kristian Eide, Marianne A. A. van Walderveen, Jeroen de Bresser, Matthias J. P. van Osch, Lydiane Hirschler

    Cerebrospinal fluid (CSF) is thought to facilitate brain waste clearance and immune surveillance, yet its compartmentalization remains unclear. Previous work, using invasive dynamic intrathecal MRI contrast imaging, identified a perivascular subarachnoid space (PVSAS) that enhances along the major cerebral arteries with a ‘donut’-like appearance. These findings suggest that the PVSAS may be separated from the surrounding broader subarachnoid space (SAS) by a semipermeable perivascular membrane. To investigate if the PVSAS could be observed non-invasively in healthy controls, we used a magnetic resonance imaging technique, CSF-STREAM (CSF-Selective T 2 -prepared REadout with Acceleration and Mobility-encoding), that assesses CSF-mobility at a high spatial resolution by isolating CSF from blood and tissue signal. Here, we observe high CSF-mobility next to the vasculature, with a steep drop-off into the surrounding SAS around both the middle and anterior cerebral arteries, suggesting the presence of the PVSAS in healthy controls. We find that CSF dynamics may be more spatially distinct than previously thought, providing a possible foundation for understanding brain CSF patterns in health and disease.


  • Open Access

    Multimodal 7T MRI Characterization of Neurodegeneration, Iron Accumulation and Neuroinflammation in the Basal Ganglia in Huntington’s Disease: The IMAGINE-HD Study

    by Nadine Anniek van de Zande, Jeroen de Bresser, Louise van der Weerd, Itamar Ronen, Susanne T. De Bot, Chloe Najac

    Introduction: In Huntington’s Disease (HD), clinical markers can be subjective and variable, highlighting the need for objective, quantitative biomarkers of disease state and progression. Given that neurodegeneration, iron accumulation, and neuroinflammation in the basal ganglia are associated with HD pathophysiology, this study aimed to investigate their potential as biomarkers. Methods: Eighty-two participants (25 premanifest, 20 early manifest, and 12 moderate manifest HD, and 25 controls) underwent 7T MRI. Volumes of the basal ganglia were derived from T1-weighted images, susceptibility, reflecting iron content, was quantified using quantitative susceptibility mapping, and myo-inositol (Ins/tCr) was measured using ¹H-MRS. Group differences were assessed using ANCOVAs adjusted for relevant covariates. Associations among imaging modalities, and with CAG-Age Product (CAP) score were examined using correlation and linear regression analyses.Results: Putaminal volume was lower and magnetic susceptibility was higher in the premanifest group compared with controls. In early manifest HD, caudate and pallidal volume and susceptibility were significantly lower and higher, respectively, relative to controls and premanifest HD. Ins/tCr was significantly higher in the moderate manifest group compared to all other groups. All imaging markers correlated with CAP scores. Multimodal correlation analyses showed negative correlation between regional susceptibility and volume, and total basal ganglia susceptibility correlated positively with Ins/tCr.Discussion: Iron accumulation and neurodegeneration showed alterations at similar disease stages, with putaminal changes already at the premanifest stage. Neuroinflammatory alterations were observed in the more advanced disease stage and correlated with iron deposition. The results highlight the value of multimodal imaging to capture complementary pathophysiological mechanisms.

  • Open Access

    A plug-and-play method for guided multi-contrast MRI reconstruction based on content/style modeling

    by Chinmay Rao, Matthias van Osch, Nicola Pezzotti, Jeroen de Bresser, Mark van Buchem, Laurens Beljaards, Jakob Meineke, Elwin de Weerdt, Huangling Lu, Mariya Doneva, et al.

  • Open Access

    Cerebral “Dirty-Appearing” White Matter in Relation to Cognitive Decline and Dementia Risk in Community-Dwelling Older Adults

    by Ingmar Eiling, Sigurdur Sigurdsson, Jasmin Annica Kuhn-Keller, Simon P. Mooijaart, Lenore J. Launer, Matthias J.P. Van Osch, Vilmundur Gudnason, Jeroen de Bresser

    Background and ObjectivesCerebral “dirty-appearing” or “diffusely abnormal” white matter (DAWM) represents subtle white matter abnormalities that are associated with progression of cerebral small v...


  • Top Cited Papers
    Open Access

    Prediction and risk evaluation of delirium after surgery in older patients: development and internal validation of an algorithm from the prospective BioCog cohort study

    by Florian Lammers-Lietz, Levent Akyuez, Diana Boraschi, Friedrich Borchers, Jeroen de Bresser, Sreyoshi Chatterjee, Marta M. Correia, Nikola M. de Lange, Thomas Bernd Dschietzig, Soumyabrata Ghosh, et al.


  • Top Cited Papers

    Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study

    by Leon D. Kaulen, Lakshmi Nayak, Philipp Karschnia, Imke Kraai, Daniela Raffaela Galluzzo, Fleur A de Groot, Matthew Witterholt, Laura Donovan, Sita Bhella, Luis P. Kuschel, et al.

    Immunodeficiency-associated primary CNS lymphoma (ID-PCNSL) represents a clinicopathologically distinct PCNSL subtype, for which large studies and prognostic models are lacking. To address this gap, the International PCNSL Collaborative Group conducted an international retrospective multi-center study, integrating clinical, radiological, and pathological data from 308 ID-PCNSL, diagnosed at 23 participating sites in 7 countries. Pre-existing immunodeficiency included administration of immunosuppressants for transplantation (41.2%) or autoimmunity (36.7%), and HIV infection (21.7%). All tumors were diffuse large B-cell lymphomas, with Epstein-Barr virus (EBV) detected in 79.2%. Immune reconstitution together with rituximab-methotrexate-(RM)-based chemotherapy was associated with highest response rates and prolonged progression-free survival, irrespective of immunodeficiency subtype and EBV status. Survival outcomes were highly variable with a 54-month median overall survival. Multivariable Cox regression identified age (per year increment HR: 1.05 (95%-CI:1.02-1.07); p < 0.001), Karnofsky Performance status (KPS) < 70 (HR: 3.10 (95%-CI:1.67-5.87); p < 0.001), EBV positivity (HR: 3.26 (95%-CI:1.47-7.33); p = 0.004) as prognostic factors for OS. A prognostic score was developed based on the sum of these adverse variables (age > 60 years, KPS < 70, EBV positivity). Stratification by this score yielded median survival times of 135, 29, and 3 months in patients with up to one, two and three unfavorable markers (p < 0.0001). It allowed improved prognostic stratification of ID-PCNSL as compared to the well-established MSKCC and IELSG models developed for immunocompetent PCNSL. Collectively, this large international cohort defines clinicobiologic features of ID-PCNSL and introduces an easily applicable prognostic system with potential to guide future management.


  • Open Access

    Primary central nervous system lymphoma—current standards and recent developments

    by Matthijs Van Der Meulen, Joost S P Vermaat, Norbert Galldiks, Samar Issa, Jeroen De Bresser, Jeanette K Doorduijn, Jacoline E C Bromberg

    Primary central nervous system lymphoma (PCNSL) is a rare aggressive B-cell non-Hodgkin lymphoma confined to the central nervous system, without systemic involvement. The incidence has increased over the past 3 decades. The prognosis has improved in patients up to 70 years old, and this type of lymphoma can be potentially cured. The gold standard of diagnosing PCNSL is histological, usually on a brain biopsy specimen via a neurosurgical procedure. Recent developments in both imaging and laboratory analyses of the cerebrospinal fluid, can be helpful in narrowing the differential diagnosis, diagnosing PCNSL itself, and in follow-up after treatment. This narrative review gives an overview of the epidemiology, diagnosis, and treatment of PCNSL, with an emphasis on recent developments in diagnostic techniques and treatment.


  • Open Access

    The White Matter Hyperintensity Shape and Brain Clearance (WHIMAS) Study for Identification of Novel 7T Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease: Protocol for a Cross-Sectional Study

    by Jasmin Annica Kuhn-Keller, Ingmar Eiling, Lydiane Hirschler, Lena Václavů, Marie-Noëlle Witjes-Ané, Marjolein Wijngaarden, Martijn Nagtegaal, Ece Ercan, Nathaly Rius Ottenheim, Marjan van der Elst, et al.

    Background: Sporadic cerebral small vessel disease (SVD) has a heterogeneous underlying pathology, and current SVD magnetic resonance imaging (MRI) markers do not accurately capture this heterogeneity. Novel ultrahigh-field (7T) brain MRI markers provide a window of opportunity to study early changes and potential determinants of SVD. White matter hyperintensity (WMH) shape is a relatively novel MRI marker of SVD and has shown prognostic potential. However, the exact microstructural changes within or surrounding WMHs or potential causes related to WMH shape variations are unknown. Furthermore, impaired brain clearance via the recently discovered brain clearance system may be another early change or potential cause of SVD. Objective: In the White Matter Hyperintensity Shape and Brain Clearance (WHIMAS) study, we aim to assess the link between WMHs—their shape in particular—and brain clearance and other MRI markers on ultrahigh-field (7T) brain MRI and show whether these markers are associated with cognitive functioning in older adults with memory complaints. Methods: This is a cross-sectional study conducted at the Leiden University Medical Center. A total of 50 outpatients from the memory or geriatric clinic aged ≥65 years will be recruited for a 3T and 7T MRI scan (including clinical structural scans, eg, 3D T1-weighted, 3D fluid-attenuated inversion recovery), and experimental scans such as cerebrospinal fluid (CSF)–selective T2-prepared readout with acceleration and mobility encoding (CSF-STREAM) and the relationship between blood oxygen level–dependent [BOLD] signals and CSF flow) and magnetic resonance fingerprinting, as well as a standardized neuropsychological test battery (domains: memory, executive function, visuoconstruction, and processing speed). We will assess WMH shape markers (solidity, convexity, concavity index, fractal dimension, and eccentricity) and brain clearance markers (CSF mobility and the relationship between blood oxygen level–dependent signals and CSF flow) and study their relationship to other MRI markers and cognitive functioning using multivariable regression analyses. Results: Patient inclusion started in January 2023, and study enrollment of patients is expected to finish in the second quarter of 2027, whereas the main results are expected to be published in the first quarter of 2028. Conclusions: We aim to understand variations in WMH shape and find their relationship to cerebral SVD and markers of brain clearance and cognitive functioning. WMH shape and brain clearance markers early in the disease process of SVD are extremely important as they may represent a basis for future patient selection for lifestyle interventions or for treatment trials aimed at the prevention of dementia. Trial Registration: ClinicalTrials.gov NCT06010511; https://clinicaltrials.gov/study/NCT06010511 International Registered Report Identifier (IRRID): DERR1-10.2196/77681